You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Overview

Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1 of SPC).1
Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.1

Reference:

  1. Volibris Summary of Product Characteristics (SPC). Available at http://www.medicines.ie/medicine/15338/SPC/Volibris+5+mg+and+10+mg+film-coated+tablets/. Last Accessed - May 2019.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority,
Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie . Adverse events should also be reported to GlaxoSmithKline on
1800 244 255.

Volibris is a registered trademark of Gilead, used under licence by the GlaxoSmithKline Group of Companies.